Acute Myeloid Leukemia Archives - Page 4 of 27

Midostaurin Maintenance Improved Survival in FLT3-Mutated Acute Myeloid Leukemia

By

Vicki Moore, PhD

September 30, 2022

Researchers sought to determine the efficacy of midostaurin maintenance therapy in patients with FLT3-mutated acute myeloid leukemia.

Hematologic Cancers

Integrating KMT2A-PTD into DNA NGS to Predict Outcomes in AML, MDS

By

Jonathan Goodman, MPhil

September 1, 2022

Integrating the assessment of KMT2A-PTD into standard DNA sequencing may be prognostically valuable for patients with MDS or AML.

Hematologic Cancers

Adding Idasanutlin to Cytarabine Does Not Improve OS in Relapsed/Refractory AML

By

Jonathan Goodman, MPhil

August 17, 2022

Researchers sought to determine whether adding idasanutlin to cytarabine would improve OS in patients with relapsed or refractory acute myeloid leukemia.

Hematologic Cancers

Similar OS, More Infections With CPX-351 vs Venetoclax Plus Azacitidine

By

Andrea S. Blevins Primeau, PhD, MBA

August 12, 2022

Researchers found similar survival, but more infections and longer hospitalizations, with CPX-351 vs venetoclax plus azacitidine.

Conferring with a patient about treatment.

Hematologic Cancers

Enasidenib in Relapsed/Refractory IDH2-Mutated Acute Myeloid Leukemia

By

Vicki Moore, PhD

July 20, 2022

Enasidenib did not improve overall survival, but it was associated with improvements in event-free survival and time to treatment failure.

EHA 2022

Extended Decitabine Appears Safer Than Standard Induction for Older AML Patients

By

Leah Lawrence

June 13, 2022

Extended decitabine produced a similar overall survival rate as standard chemotherapy, but decitabine had a better safety profile.

EHA 2022

Quizartinib Improves Overall Survival in FLT3-ITD+ Acute Myeloid Leukemia

By

Leah Lawrence

June 12, 2022

Results from the phase 3 QuANTUM-First trial have the potential to change standard care for adults with newly diagnosed FLT3-ITD+ acute myeloid leukemia, according to the lead study author.